Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) announced a quarterly dividend on Wednesday, July 17th, Zacks reports. Stockholders of record on Friday, August 16th will be given a dividend of 0.21 per share by the biopharmaceutical company on Friday, September 13th. This represents a $0.84 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Friday, August 16th.
Royalty Pharma has raised its dividend by an average of 38.7% per year over the last three years. Royalty Pharma has a payout ratio of 19.2% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Royalty Pharma to earn $4.37 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 19.2%.
Royalty Pharma Price Performance
RPRX stock opened at $28.33 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 12.52 and a current ratio of 12.52. The business has a 50-day simple moving average of $26.91 and a two-hundred day simple moving average of $28.37. The company has a market capitalization of $16.93 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 3.66 and a beta of 0.46. Royalty Pharma has a 52-week low of $25.20 and a 52-week high of $31.66.
Wall Street Analyst Weigh In
Several analysts have recently commented on the stock. UBS Group downgraded shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price for the company. in a report on Monday, June 3rd. StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Morgan Stanley boosted their target price on Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a research note on Thursday, July 11th. Finally, Bank of America decreased their price target on Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, April 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $41.80.
View Our Latest Research Report on Royalty Pharma
About Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Recommended Stories
- Five stocks we like better than Royalty Pharma
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why These 4 AI Stocks Are Must-Watch for 2024 Investors
- Investing in Commodities: What Are They? How to Invest in Them
- Pharma Leader Beats on Earnings, But Shares Fall
- How to Effectively Use the MarketBeat Ratings Screener
- Oracle Pulls Back After Musk Deal Falls Through, Time to Buy?
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.